VYNE Therapeutics
VYNE
54 hedge funds and large institutions have $12.5M invested in VYNE Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 19 closing their positions.
265% more call options, than puts
Call options by funds: $95K | Put options by funds: $26K
0.29% less ownership
Funds ownership: 1.56% → 1.27% (-0.29%)
16% less funds holding
Funds holding: 64 → 54 (-10)
38% less capital invested
Capital invested by funds: $20.1M → $12.5M (-$7.62M)
47% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 19
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DSC Advisors
Chicago,
Illinois
|
+$1.73M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$197K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$149K |
| 4 |
Goldman Sachs
New York
|
+$87.8K |
| 5 |
VF
Virtu Financial
New York
|
+$79.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$2.12M |
| 2 |
6CM
683 Capital Management
New York
|
-$994K |
| 3 |
Renaissance Technologies
New York
|
-$406K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$227K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
-$200K |
VYNE Hedge Fund Activity: Q4 2021 in Review
54 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2021, worth a combined $12.5M — down 38% from $20.1M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of VYNE and 10 opened new positions — a net loss of 9 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was DSC Advisors, adding an estimated $1.73M. The largest seller was Franklin Resources, cutting an estimated $2.12M.
- 54 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2021, down from 64 in Q3 2021.
- Funds reported $12.5M of VYNE Therapeutics stock for Q4 2021, down 38% quarter-over-quarter.
- 10 funds opened new VYNE Therapeutics positions in Q4 2021 and 19 closed out, a net change of -9 holders.
- The largest VYNE Therapeutics buyer in Q4 2021 was DSC Advisors, an estimated $1.73M added.
- The largest VYNE Therapeutics seller in Q4 2021 was Franklin Resources, an estimated $2.12M sold.
Based on aggregated 13F filings for Q4 2021.